Assessment of eptifibatide dosing in renal impairment before and after in-service education provided by pharmacists

Journal of Managed Care Pharmacy

Volumn 13, Issue 7, 2007, Pages 598-606

  Donovan, Jennifer L ^a,b   Schroeder, Walter S ^c,d   Tran, Maichi T ^b   Foster, Keith ^e   Forrest, Alan ^c   Lee, Tamara B ^f   Gandhi, Pritesh J ^g  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e UNIVERSITY OF MASSACHUSETTS   (United States)

^f ROSEMAN UNIVERSITY OF HEALTH SCIENCES   (United States)

^g GENZYME CORPORATION   (United States)

Author keywords

Clinical pharmacist; Dosing guideline; Educational intervention; Eptifibatide; Renal impairment

Indexed keywords

EPTIFIBATIDE;

AGED; ARTICLE; BLEEDING TENDENCY; CONTINUOUS INFUSION; CREATININE CLEARANCE; EDUCATION PROGRAM; FEMALE; HEALTH EDUCATION; HEART INFARCTION; HUMAN; INCIDENCE; INTERVENTION STUDY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NON ST ELEVATION MYOCARDIAL INFARCTION; PATIENT ASSESSMENT; PHARMACIST; PRACTICE GUIDELINE; RENAL DOSING RECOMMENDATION; RISK ASSESSMENT; UNSTABLE ANGINA PECTORIS;

EID: 35348965790     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.7.598     Document Type: Article

References (22)

1. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274:29-34.
2. Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA. 1995;274:35-43.
3. Kohn KT, Corrigan JM, Donaldson MS. To err is human: building a safer health system. Washington, DC: National Academy of Sciences, Institute of Medicine; 1999. Report no.: R729.8.T6 2000.
4. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. ADE Prevention Study Group. JAMA. 1997;277:307-11.
5. Fanikos J, Stapinski C, Koo S, et al. Medication errors associated with anticoagulant therapy in the hospital. Am J Cardiol. 2004;94:532-35.
6. Institute for Safe Medication Practices. (2007). ISMP's List of High-Alert Medications. Available at http://www.ismp.org/tools/ highalertmedications.pdf. Accessed August 25, 2007.
7. Saxer SB, Smith BS, Gandhi PJ, Tataronis GR, Krikorian SA. Recommended and actual lepirudin doses in patients with renal insufficiency. Am J Health Syst Pharm. 2003;60:2588-93.
8. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108-16.
9. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277:301-06.
10. Winterstein AG, Hatton RC, Gonzalez-Rothi R, Johns TE, Segal R. Identifying clinically significant preventable adverse drug events through a hospital's database of adverse drug reaction reports. Am J Health Syst Pharm. 2002;59:1742-49.
11. Eptifibatide package insert. Kenilworth, NJ. Schering Corporation; June 2005.
12. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circ. 2004;110:588-636.
13. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (ACC/AHA/SCAI writing committee to update 2001 guidelines for percutaneous coronary intervention). Circ. 2006;113:e166-e286.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
15. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356:2037-44.
16. Gretler DD, Guerciolini R, Williams PJ. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Clin Ther. 2004;26:390-98.
17. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the enoxaparin and thrombolysis reperfusion for acute myocardial infarction treatment-thrombolysis in myocardial infarction study 25 (ExTRACT-TIMI 25). Am Heart J. 2005;149:217-26.
18. Schunemann HJ, Cook D, Grimshaw J, et al. Antithrombotic and thrombolytic therapy: from evidence to application: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:688S-696S.
19. Grimshaw JM, Thomas RE, MacLennan G, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess. 2004;8:iii-iv, 1-72.
20. Tooher R, Middleton P, Pham C, et al. A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. Ann Surg. 2005;241:397-415.
21. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrum to minimise platelet aggregation and coronary thrombosis (IMPACT)-II. Lancet. 1997;349:1422-28.
22. The PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT). N Engl J Med. 1998;339:436-43.